Atara Biotherapeutics Amends Agreement, Delays $9M Payment to 2028
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ATRA?
Atara Biotherapeutics announced that the company entered into an amendment to the purchase and sale agreement dated as of December 20, 2022 with a fund managed by HealthCare Royalty. Under the terms of the amendment, HCRx agreed to amend the due date of the one-time of $9M cash payment associated with the achievement of a certain milestone within the amended and restated commercialization agreement dated October 31, 2023, with Pierre Fabre Medicament, as amended, from June 30 to January 1, 2028. In connection with the amendment, the company issued a warrant to purchase up to 400,000 shares of the company's common stock. The exercise price of the warrant is equal to $0.0001 per share, subject to adjustment as provided therein, and the warrants will be exercisable immediately and have no expiration date. The exercise of the warrant is subject to a beneficial ownership limit as set forth in the warrant.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.170
Low
18.00
Averages
21.50
High
25.00
Current: 5.170
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to significant financial losses for investors and negatively impacted the company's reputation and market confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Reminder of Class Action Lawsuit for Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the regulatory prospects of its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Legal Counsel Selection: The firm advises investors to be cautious in selecting legal counsel, recommending those with a proven track record in securities class actions to avoid partnering with inexperienced intermediaries, ensuring effective legal representation.
- Historical Achievements: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and influence in the securities litigation field.
See More
Atara Biotherapeutics Securities Fraud Class Action Reminder
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, alleging false statements regarding the regulatory prospects of the tabelecleucel BLA, which may lead to significant investor losses.
- Stock Price Volatility: On January 16, 2025, Atara's stock plummeted by $5.33, a decline of approximately 40.5%, from $13.16 to $7.83, following the receipt of a Complete Response Letter (CRL) from the FDA, highlighting the direct impact of regulatory risks on the company's financial condition.
- Clinical Trial Hold: The FDA placed a clinical hold on Atara's IND applications on January 21, 2025, due to unresolved GMP compliance issues, causing the stock to drop by $0.52, or about 8%, indicating significant obstacles in the company's clinical development.
- Latest CRL Impact: On January 12, 2026, Atara announced another CRL from the FDA, resulting in a $7.79 drop in stock price, approximately 57%, from $13.67 to $5.88, underscoring the severe challenges the company faces in bringing its product to market and the potential long-term implications for its business.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements Issue: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing problems, making FDA approval of its BLA for tabelecleucel unlikely, thus overstating the product's prospects and leading to investor losses.
- Increased Regulatory Risk: Atara faces heightened regulatory action risks due to manufacturing deficiencies, rendering its public statements false and materially misleading, which exacerbates investor confidence issues and potential market repercussions.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations, highlighting its commitment to protecting shareholder rights.
See More
Faruqi & Faruqi Investigates Potential Claims Against Atara Biotherapeutics
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating possible legal risks that could undermine investor confidence.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating prompt action from investors to protect their rights, which may impact the company's stock performance.
- Direct Contact Encouragement: Partner Josh Wilson encourages investors who purchased Atara securities during the specified period to contact him directly for legal consultation, demonstrating the firm's commitment to supporting its clients.
- Potential Litigation Impact: Should the investigation substantiate claims, Atara may face significant financial liabilities, potentially affecting its market performance and investor confidence, highlighting the legal risks that could threaten the company's operations.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, alleging the company misled investors regarding its drug candidate's manufacturing issues.
- Regulatory Scrutiny Risks: The complaint highlights that deficiencies in the ALLELE study make FDA approval of tabelecleucel's Biologics License Application (BLA) unlikely, which not only jeopardizes the company's regulatory prospects but also poses significant risks to ongoing clinical trials and overall financial health.
- Stock Price Plunge: Following a press release on January 12, 2026, announcing another Complete Response Letter (CRL) from the FDA regarding tabelecleucel, Atara's stock price fell by $7.79, or 56.99%, closing at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, emphasizing the importance of corporate governance and executive accountability, with all representation on a contingency fee basis, requiring no upfront payment.
See More
Reminder for Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to significant financial losses for investors and negatively impacted the company's reputation and market confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Reminder of Class Action Lawsuit for Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the regulatory prospects of its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Legal Counsel Selection: The firm advises investors to be cautious in selecting legal counsel, recommending those with a proven track record in securities class actions to avoid partnering with inexperienced intermediaries, ensuring effective legal representation.
- Historical Achievements: Rosen Law Firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities and influence in the securities litigation field.
See More
Atara Biotherapeutics Securities Fraud Class Action Reminder
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, alleging false statements regarding the regulatory prospects of the tabelecleucel BLA, which may lead to significant investor losses.
- Stock Price Volatility: On January 16, 2025, Atara's stock plummeted by $5.33, a decline of approximately 40.5%, from $13.16 to $7.83, following the receipt of a Complete Response Letter (CRL) from the FDA, highlighting the direct impact of regulatory risks on the company's financial condition.
- Clinical Trial Hold: The FDA placed a clinical hold on Atara's IND applications on January 21, 2025, due to unresolved GMP compliance issues, causing the stock to drop by $0.52, or about 8%, indicating significant obstacles in the company's clinical development.
- Latest CRL Impact: On January 12, 2026, Atara announced another CRL from the FDA, resulting in a $7.79 drop in stock price, approximately 57%, from $13.67 to $5.88, underscoring the severe challenges the company faces in bringing its product to market and the potential long-term implications for its business.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements Issue: The complaint alleges that Atara made false and misleading statements regarding its ALLELE study, which suffered from manufacturing problems, making FDA approval of its BLA for tabelecleucel unlikely, thus overstating the product's prospects and leading to investor losses.
- Increased Regulatory Risk: Atara faces heightened regulatory action risks due to manufacturing deficiencies, rendering its public statements false and materially misleading, which exacerbates investor confidence issues and potential market repercussions.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover losses, with the Schall Law Firm specializing in securities class actions and offering free consultations, highlighting its commitment to protecting shareholder rights.
See More
Faruqi & Faruqi Investigates Potential Claims Against Atara Biotherapeutics
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for the period between May 20, 2024, and January 9, 2026, indicating possible legal risks that could undermine investor confidence.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, necessitating prompt action from investors to protect their rights, which may impact the company's stock performance.
- Direct Contact Encouragement: Partner Josh Wilson encourages investors who purchased Atara securities during the specified period to contact him directly for legal consultation, demonstrating the firm's commitment to supporting its clients.
- Potential Litigation Impact: Should the investigation substantiate claims, Atara may face significant financial liabilities, potentially affecting its market performance and investor confidence, highlighting the legal risks that could threaten the company's operations.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds shareholders that a class action has been filed on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, alleging the company misled investors regarding its drug candidate's manufacturing issues.
- Regulatory Scrutiny Risks: The complaint highlights that deficiencies in the ALLELE study make FDA approval of tabelecleucel's Biologics License Application (BLA) unlikely, which not only jeopardizes the company's regulatory prospects but also poses significant risks to ongoing clinical trials and overall financial health.
- Stock Price Plunge: Following a press release on January 12, 2026, announcing another Complete Response Letter (CRL) from the FDA regarding tabelecleucel, Atara's stock price fell by $7.79, or 56.99%, closing at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, emphasizing the importance of corporate governance and executive accountability, with all representation on a contingency fee basis, requiring no upfront payment.
See More
